Joshua James
Overview
Energetic and committed, Joshua James helps clients strengthen and enforce their intellectual property rights. Josh’s practice focuses on patent litigation, particularly Hatch-Waxman pharmaceutical litigation in federal courts and inter partes review proceedings before the Patent Trial and Appeal Board.
Career & Education
- Illinois Institute of Technology (IIT)
Research Experience for Undergraduates, June 2010–August 2011
Inter-Professional Research Opportunity (IPRO), January 2011–May 2011
Biomedical Engineering Senior Design, August 2009–May 2010
Research Experience for Undergraduates, June 2009–August 2009 - Rehabilitation Institute of Chicago
Research Experience for Undergraduates, June 2008–August 2008
- Illinois Institute of Technology (IIT)
- Illinois Institute of Technology, B.S., Summa cum Laude, chemical engineering, 2011
- Illinois Institute of Technology, B.S., Summa cum Laude, biomedical engineering, 2011
- Indiana University - Bloomington, Maurer School of Law, J.D., cum Laude, 2014
- Illinois
- U.S. Patent and Trademark Office (USPTO)
- U.S. District Court for the Northern District of Illinois
- U.S. Court of Appeals for the Federal Circuit
- Supreme Court of the United States
Professional Activities and Memberships
- PTAB Bar Association, 2016–present
- American Intellectual Property Law Association, 2011–present
- Chicago Bar Association, 2015–present
- Indiana Law Journal, Board Member, 2013–2014
- Intellectual Property Association, 2011–2014
- Phi Alpha Delta, Clerk, 2013
Joshua 's Insights
Client Alert | 4 min read | 04.29.24
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents
As reported in an earlier Client Alert, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In the letters, the FTC indicated it is using the FDA’s regulatory dispute process to challenge the listing of these patents in the Orange Book because improperly listed patents may violate antitrust laws and impede competition.
Client Alert | 3 min read | 11.16.23
Firm News | 9 min read | 08.17.23
Recognition
- Illinois Institute of Technology: Biomedical Engineering Distinguished Undergraduate Alumnus, 2017
- Indiana University Maurer School of Law: Dean’s Honors, Fall 2011, Spring/Fall 2013
- Illinois Institute of Technology: Camras Scholarship, Dean’s List, and Tau Beta Pi, 2007–2011
Joshua 's Insights
Client Alert | 4 min read | 04.29.24
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents
As reported in an earlier Client Alert, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In the letters, the FTC indicated it is using the FDA’s regulatory dispute process to challenge the listing of these patents in the Orange Book because improperly listed patents may violate antitrust laws and impede competition.
Client Alert | 3 min read | 11.16.23
Firm News | 9 min read | 08.17.23
Insights
Joshua 's Insights
Client Alert | 4 min read | 04.29.24
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents
As reported in an earlier Client Alert, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In the letters, the FTC indicated it is using the FDA’s regulatory dispute process to challenge the listing of these patents in the Orange Book because improperly listed patents may violate antitrust laws and impede competition.
Client Alert | 3 min read | 11.16.23
Firm News | 9 min read | 08.17.23
